Acute Lymphoblastic Leukemia

Blincyto approval expanded for specific leukemia

(HealthDay)—The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who ...

Mar 30, 2018
popularity1 comments 0

New insights into treating a rare leukemia

A study at Children's Hospital Los Angeles is shedding new light on the best therapeutic approach for a rare and aggressive leukemia called mixed phenotype acute leukemia (MPAL).

Feb 27, 2018
popularity45 comments 0

Two genes cooperate to trigger leukemia development

An international group of researchers led by Prof. Jan Cools of the VIB-KU Leuven Center for Cancer Biology have made a breakthrough in understanding the development of acute lymphoblastic leukemia, an aggressive cancer of ...

Mar 20, 2018
popularity6 comments 0

CRISPR enhances cancer immunotherapy

Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells—called T cells—and supercharging them to home in ...

Mar 06, 2018
popularity18 comments 0

Enabling technology for emerging gene therapies

For years, researchers have attempted to harness the full potential of gene therapy, a technique that inserts genes into a patient's cells to treat aggressive diseases such as cancer. But getting engineered DNA molecules ...

Feb 27, 2018
popularity1 comments 0

Acute lymphoblastic leukemia (ALL) is a form of leukemia, or cancer of the white blood cells characterized by excess lymphoblasts.

Malignant, immature white blood cells continuously multiply and are overproduced in the bone marrow. ALL causes damage and death by crowding out normal cells in the bone marrow, and by spreading (infiltrating) to other organs. ALL is most common in childhood with a peak incidence at 2–5 years of age, and another peak in old age. The overall cure rate in children is about 80%, and about 45%-60% of adults have long-term disease-free survival.

Acute refers to the relatively short time course of the disease (being fatal in as little as a few weeks if left untreated) to differentiate it from the very different disease of chronic lymphocytic leukemia, which has a potential time course of many years. It is interchangeably referred to as Lymphocytic or Lymphoblastic. This refers to the cells that are involved, which if they were normal would be referred to as lymphocytes but are seen in this disease in a relatively immature (also termed 'blast') state.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News